Growth Hormone and IGF-1 Actions in the Brain and Neuropsychiatric Diseases
Physiology · 01.01.2026 · 41 (1) · 3-15
DOI: 10.1152/physiol.00009.2025 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Physiology, erschienen am 01.01.2026. Verfasst von Manuel H Aguiar-Oliveira und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Health Sciences Graduate Program, Federal University of Sergipe, Aracaju, Brazil. Hauptthemen laut MEDLINE: Insulin-Like Growth Factor I, Brain, Mental Disorders, Growth Hormone. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), NIMH NIH HHS, HHS | NIH | National Institute of Mental Health (NIMH).
Abstract (Originalsprache)
Growth hormone (GH) is secreted by the anterior pituitary gland under the control of hypothalamic neuroendocrine neurons that express somatostatin or growth hormone-releasing hormone (GHRH). Ghrelin, originating primarily in the stomach, is also an important GH secretagogue. GH stimulates the hepatic secretion of insulin-like growth factor-1 (IGF-1) and the expression of IGF-1 in extrahepatic tissues, including the brain. Many regions of the brain express receptors for GH, IGF-1, and ghrelin. In recent decades, evidence from both human and animal studies has indicated that GH, IGF-1, and ghrelin regulate numerous brain functions. Alterations in the secretion or sensitivity to these hormones may represent risk factors for developing neurodegenerative diseases (e.g., Alzheimer’s and Parkinson’s) and neuropsychiatric conditions (such as depression, anxiety, posttraumatic stress disorder, schizophrenia, and bipolar disorder). Additionally, classical neurodevelopmental disorders such as autism spectrum and attention-deficit hyperactivity disorders may also be influenced by somatotropic hormones. This review aims to summarize and discuss the emerging role of GH and IGF-1 in influencing brain function and the predisposition to brain diseases and neuropsychiatric disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Health Sciences Graduate Program, Federal University of Sergipe, Aracaju, Brazil.
- Department of Pediatrics, Endocrine Division (SEMPR), Federal University of Parana, Curitiba, Brazil.
- Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
ORCID-Profile: Manuel H Aguiar-Oliveira, Margaret C S Boguszewski, Diego L Rovaris, Jose Donato
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
- NIMH NIH HHS
- HHS | NIH | National Institute of Mental Health (NIMH)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Zitieren
APA
Aguiar-Oliveira, M. H., Boguszewski, M. C. S., Rovaris, D. L., & Donato, J. (2026). Growth Hormone and IGF-1 Actions in the Brain and Neuropsychiatric Diseases. Physiology, 41(1), 3-15. https://doi.org/10.1152/physiol.00009.2025
Vancouver
Aguiar-Oliveira MH, Boguszewski MCS, Rovaris DL, Donato J. Growth Hormone and IGF-1 Actions in the Brain and Neuropsychiatric Diseases. Physiology. 2026;41(1):3-15. doi:10.1152/physiol.00009.2025
BibTeX
@article{AguiarOliveira2026,
author = {Aguiar-Oliveira, Manuel H and Boguszewski, Margaret C S and Rovaris, Diego L and Donato, Jose},
title = {Growth Hormone and IGF-1 Actions in the Brain and Neuropsychiatric Diseases},
journal = {Physiology},
year = {2026},
volume = {41},
number = {1},
pages = {3--15},
doi = {10.1152/physiol.00009.2025}
}
EUVIMED